PHILADELPHIA — The first-ever “bile duct-on-a-chip,” replicating the structure and cellular makeup of the human digestive organ, was created by a team at Penn Medicine, led by Rebecca Wells, MD, a professor of Gastroenterology, with Yu Du, PhD, a postdoctoral fellow in the division of Gastroenterology, as the first author. The small model — 4 millimeters long and 0.16 millimeters in diameter — now makes it possible for researchers to study the difficult-to-access tissue without the need for human participants or living animal models, which could open the door for more research into bile duct-related illness in both children and adults. A detailed explanation of the bile duct-on-a-chip and the researchers’ findings are published in the journal Hepatology.
Bile ducts are the tubes that transfer bile — a highly toxic fluid — from the liver and gallbladder to the small intestine, where it assists the body with digestion and plays a role in waste excretion. Inside the bile ducts, the lining cells called cholangiocytes are packed very tightly and can typically tolerate the highly toxic nature of bile and other substances flowing through the lumen, or the interior, of the ducts. In vitro, researchers have been studying biliary physiopathology using 2D dishes and organoids, for years. However, those models failed to replicate the ducts’ tubular structure and made it difficult to access the interior side of cholangiocytes.
“Bile ducts are not like copper pipes or garden hoses where the material on the inside is the same as the material on the outside. The inside and outside of bile ducts look very different, and our research shows they react differently when in direct contact with the liquid bile,” Wells said.
To create the chip version of the bile duct, a clear, gas permeable polymer was used as a support for collagen, through which the tiny channel was formed using an acupuncture needle. Isolated bile-duct cells, taken from mice, were placed in the channel; the cells attached to the collagen and multiplied, forming a nearly impermeable single layer of cells. By constructing an open-ended tubular structure in the device, researchers made it possible to expose separately the lumen and the outside of the impermeable mini bile duct to bile components and other toxic substances through separated ports. The creation of this bile duct-on-a-chip joins the ranks of other existing organs-on-chips including lung, kidney, and skin.
“Bile ducts pose great challenges to researchers because of their location and their complex function and cellular structure, which has made this organ historically difficult to study,” said Wells. “Creating the bile duct-on-a-chip, in a way that replicates many features of the human duct, has allowed us — and we hope will allow other researchers — to study the tissue in more detail, with greater ease. This access could open doors for more research into liver diseases such as primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and biliary atresia.”
With the help of bile ducts-on-chips, Wells and team found that bile-duct exteriors are much more sensitive to injury than the interiors and are susceptible to significant damage from bile exposure. Her team now plans to explore ways to prevent this damage and leakage, as well as to look for ways to bolster resiliency or protection of both interior and exterior parts of the ducts.
The team also notes there is a need to better understand the difference between adult and neonatal bile ducts. The chip design will allow researchers to create different “aged” ducts and explore causes and potential treatments for biliary atresia, the major cause of liver failure among infants in the United States. Babies can be born with biliary atresia, and it’s thought to originate from an infection or toxin, however, mothers of these newborns do not have any of the same issues.
“We know fetal cholangiocytes are more susceptible to injury, but we don’t yet know why a baby gets sick but the mother does not,” Wells said. She hopes bile ducts-on-chips will help investigators shed a light on the reason cholangiocytes in adults seem so much less susceptible to injury than those in fetuses and newborns.
Additional authors include Gauri Khandekar, and Jessica Llewellyn from the Perelman School of Medicine at the University of Pennsylvania, Christopher S. Chen from Boston University, and William Polacheck, now at the University of North Carolina at Chapel Hill and North Carolina State.
This study was funded by grant R56 DK119290 from the National Institutes of Diabetes and Digestive and Kidney Diseases (to RGW), the Fred and Suzanne Biesecker Foundation for Pediatric Liver Diseases at Children’s Hospital of Philadelphia, and the Center for Engineering MechanoBiology (CEMB), an NSF Science and Technology Center, under grant agreement CMMI: 15-48571.
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation’s first medical school) and the University of Pennsylvania Health System, which together form a $8.6 billion enterprise.
The Perelman School of Medicine has been ranked among the top medical schools in the United States for more than 20 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $494 million awarded in the 2019 fiscal year.
The University of Pennsylvania Health System’s patient care facilities include: the Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center—which are recognized as one of the nation’s top “Honor Roll” hospitals by U.S. News & World Report—Chester County Hospital; Lancaster General Health; Penn Medicine Princeton Health; and Pennsylvania Hospital, the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is powered by a talented and dedicated workforce of more than 43,900 people. The organization also has alliances with top community health systems across both Southeastern Pennsylvania and Southern New Jersey, creating more options for patients no matter where they live.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2019, Penn Medicine provided more than $583 million to benefit our community.